Sabby Volatility Exits Cocrystal Pharma Position
Ticker: COCP · Form: SC 13G/A · Filed: Jan 2, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | SC 13G/A |
| Filed Date | Jan 2, 2024 |
| Risk Level | medium |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: institutional-selling, divestment, ownership-change
TL;DR
**Sabby Volatility just dumped all its Cocrystal Pharma shares.**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd. filed an amended SC 13G/A for Cocrystal Pharma, Inc. on January 2, 2024, indicating they no longer beneficially own any shares of Cocrystal Pharma's common stock as of December 31, 2023. This update, filed under Rule 13d-1(c), shows a complete divestment from the pharmaceutical company. For investors, this means a significant institutional holder has exited their position, which could signal a lack of confidence or a shift in investment strategy, potentially impacting future stock performance.
Why It Matters
This filing reveals a major institutional investor, Sabby Volatility Warrant Master Fund, Ltd., has completely sold off its stake in Cocrystal Pharma, Inc., which could be interpreted negatively by the market.
Risk Assessment
Risk Level: medium — The complete divestment by an institutional investor could signal underlying concerns about the company's future, increasing investment risk.
Analyst Insight
A smart investor would consider this complete divestment by Sabby Volatility Warrant Master Fund, Ltd. as a potential red flag and conduct further due diligence into Cocrystal Pharma's fundamentals and future prospects before making any investment decisions.
Key Numbers
- 0 — Sole Voting Power (Number of shares with sole voting power beneficially owned by Sabby Volatility Warrant Master Fund, Ltd. as of December 31, 2023.)
- 0 — Shared Voting Power (Number of shares with shared voting power beneficially owned by Sabby Volatility Warrant Master Fund, Ltd. as of December 31, 2023.)
- 0 — Sole Dispositive Power (Number of shares with sole dispositive power beneficially owned by Sabby Volatility Warrant Master Fund, Ltd. as of December 31, 2023.)
- 0 — Shared Dispositive Power (Number of shares with shared dispositive power beneficially owned by Sabby Volatility Warrant Master Fund, Ltd. as of December 31, 2023.)
Key Players & Entities
- Sabby Volatility Warrant Master Fund, Ltd. (company) — the reporting person who filed the SC 13G/A
- Cocrystal Pharma, Inc. (company) — the subject company whose shares were previously held
- Cayman Islands (place) — place of organization for Sabby Volatility Warrant Master Fund, Ltd.
- December 31, 2023 (date) — date of event requiring the filing
Forward-Looking Statements
- Cocrystal Pharma's stock price may experience downward pressure due to the institutional divestment. (Cocrystal Pharma, Inc.) — medium confidence, target: Q1 2024
- Other institutional investors might re-evaluate their positions in Cocrystal Pharma following this exit. (Cocrystal Pharma, Inc.) — low confidence, target: Q1 2024
FAQ
Who filed this SC 13G/A amendment?
The SC 13G/A amendment was filed by Sabby Volatility Warrant Master Fund, Ltd., as indicated in the 'NAME OF REPORTING PERSONS' section of the filing.
What is the subject company of this filing?
The subject company is Cocrystal Pharma, Inc., as stated under 'Name of Issuer' and 'COMPANY CONFORMED NAME' in the filing.
What was the date of the event that triggered this filing?
The date of the event which requires the filing of this statement was December 31, 2023, as specified in the filing.
How many shares of Cocrystal Pharma, Inc. common stock does Sabby Volatility Warrant Master Fund, Ltd. now beneficially own?
As of December 31, 2023, Sabby Volatility Warrant Master Fund, Ltd. beneficially owns 0 shares of Cocrystal Pharma, Inc. common stock, as indicated by 'SOLE VOTING POWER 0', 'SHARED VOTING POWER 0', 'SOLE DISPOSITIVE POWER 0', and 'SHARED DISPOSITIVE POWER 0' in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the 'X' next to '[X] Rule 13d-1(c)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 2, 2024 regarding Cocrystal Pharma, Inc. (COCP).